{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:08:44Z","timestamp":1793452124778,"version":"4.5.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG073291"],"award-info":[{"award-number":["R01AG073291"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG071820"],"award-info":[{"award-number":["R01AG071820"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG079487"],"award-info":[{"award-number":["RF1AG079487"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01AG056841"],"award-info":[{"award-number":["K01AG056841"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P50 AG05146"],"award-info":[{"award-number":["P50 AG05146"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG085688"],"award-info":[{"award-number":["R01 AG085688"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG089605"],"award-info":[{"award-number":["R01AG089605"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008539","name":"CurePSP","doi-asserted-by":"publisher","award":["658-2018-06"],"award-info":[{"award-number":["658-2018-06"]}],"id":[{"id":"10.13039\/100008539","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AFAR New Investigator Award in Alzheimer\u2019s disease","award":["AFAR New Investigator Award in Alzheimer\u2019s disease"],"award-info":[{"award-number":["AFAR New Investigator Award in Alzheimer\u2019s disease"]}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS107318"],"award-info":[{"award-number":["R01NS107318"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1NS125592"],"award-info":[{"award-number":["RF1NS125592"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS125559"],"award-info":[{"award-number":["R21NS125559"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1NS137428"],"award-info":[{"award-number":["RF1NS137428"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson\u2019s Foundation","doi-asserted-by":"crossref","award":["PF-JFA-1933"],"award-info":[{"award-number":["PF-JFA-1933"]}],"id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Maryland Stem Cell Research Foundation","award":["2019-MSCRFD-4292"],"award-info":[{"award-number":["2019-MSCRFD-4292"]}]},{"DOI":"10.13039\/100006309","name":"American Parkinson Disease Association","doi-asserted-by":"publisher","award":["American Parkinson Disease Association"],"award-info":[{"award-number":["American Parkinson Disease Association"]}],"id":[{"id":"10.13039\/100006309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","award":["JPB Foundation"],"award-info":[{"award-number":["JPB Foundation"]}],"id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018231","name":"Aligning Science Across Parkinson\u2019s","doi-asserted-by":"publisher","award":["Aligning Science Across Parkinson\u2019s"],"award-info":[{"award-number":["Aligning Science Across Parkinson\u2019s"]}],"id":[{"id":"10.13039\/100018231","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Farmer Family Foundation Parkinson\u2019s Research Initiative","award":["Farmer Family Foundation Parkinson\u2019s Research Initiative"],"award-info":[{"award-number":["Farmer Family Foundation Parkinson\u2019s Research Initiative"]}]},{"name":"Farmer Family Foundation Parkinson\u2019s Research Initiative","award":["Farmer Family Foundation Parkinson\u2019s Research Initiative"],"award-info":[{"award-number":["Farmer Family Foundation Parkinson\u2019s Research Initiative"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\u03b1-Synucleinopathies constitute a spectrum of neurodegenerative disorders, including Parkinson\u2019s disease (PD), Lewy body dementia (LBD), Multiple System Atrophy (MSA), and Alzheimer\u2019s disease concurrent with LBD (AD-LBD). These disorders are unified by a pathological hallmark: aberrant misfolding and accumulation of \u03b1-synuclein (\u03b1-syn). This review delves into the pivotal role of \u03b1-syn, the key agent in \u03b1-synucleinopathy pathophysiology, and provides a survey of potential therapeutics that target cell-to-cell spread of pathologic \u03b1-syn. Recognizing the intricate complexity and multifactorial etiology of \u03b1-synucleinopathy, the review illuminates the potential of various membrane receptors, proteins, intercellular spreading pathways, and pathological agents for therapeutic interventions. While significant progress has been made in understanding \u03b1-synucleinopathy, the pursuit of efficacious treatments remains challenging. Several strategies involving decreasing \u03b1-syn production and aggregation, increasing \u03b1-syn degradation, lowering extracellular \u03b1-syn, and inhibiting cellular uptake of \u03b1-syn are presented. The paper underscores the necessity of meticulous and comprehensive investigations to advance our knowledge of \u03b1-synucleinopathy pathology and ultimately develop innovative therapeutic strategies for \u03b1-synucleinopathies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13024-025-00797-1","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:43:50Z","timestamp":1737611030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Emerging targets of \u03b1-synuclein spreading in \u03b1-synucleinopathies: a review of mechanistic pathways and interventions"],"prefix":"10.1186","volume":"20","author":[{"given":"Grace","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramhari","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valina L.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-556X","authenticated-orcid":false,"given":"Xiaobo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"3","key":"797_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, et al. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14(3):176.","journal-title":"Cell Death Dis"},{"issue":"6","key":"797_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron. 2013;79(6):1044\u201366.","journal-title":"Neuron"},{"key":"797_CR3","doi-asserted-by":"crossref","unstructured":"Kumari P et al. Structural insights into alpha-synuclein monomer-fibril interactions. Proc Natl Acad Sci U S A, 2021. 118(10).","DOI":"10.1073\/pnas.2012171118"},{"key":"797_CR4","doi-asserted-by":"crossref","unstructured":"Zhang S et al. Mechanistic basis for receptor-mediated pathological alpha-synuclein fibril cell-to-cell transmission in Parkinson\u2019s disease. Proc Natl Acad Sci U S A, 2021. 118(26).","DOI":"10.1073\/pnas.2011196118"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.arr.2019.01.012","volume":"50","author":"JY Vargas","year":"2019","unstructured":"Vargas JY, Grudina C, Zurzolo C. The prion-like spreading of alpha-synuclein: from in vitro to in vivo models of Parkinson\u2019s disease. Ageing Res Rev. 2019;50:89\u2013101.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"797_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-022-00560-w","volume":"17","author":"K Chen","year":"2022","unstructured":"Chen K, et al. LRP1 is a neuronal receptor for alpha-synuclein uptake and spread. Mol Neurodegener. 2022;17(1):57.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"797_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13024-022-00582-4","volume":"17","author":"C Pan","year":"2022","unstructured":"Pan C, Peng C. LRP1: a novel receptor for the transmission of pathological alpha-synuclein. Mol Neurodegener. 2022;17(1):79.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"797_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s12035-022-03119-4","volume":"60","author":"R Huang","year":"2023","unstructured":"Huang R, et al. Endothelial LRP1-ICD accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 activation in a mouse model of Parkinson\u2019s Disease. Mol Neurobiol. 2023;60(2):979\u20131003.","journal-title":"Mol Neurobiol"},{"key":"797_CR9","unstructured":"Mao X et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016. 353(6307)."},{"key":"797_CR10","doi-asserted-by":"publisher","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","volume":"42","author":"E Ruffo","year":"2019","unstructured":"Ruffo E, et al. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019;42:101305.","journal-title":"Semin Immunol"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"p656426","DOI":"10.3389\/fncel.2021.656426","volume":"15","author":"H Gu","year":"2021","unstructured":"Gu H, et al. Lymphocyte activation gene 3 (Lag3) contributes to alpha-synucleinopathy in alpha-synuclein transgenic mice. Front Cell Neurosci. 2021;15:p656426.","journal-title":"Front Cell Neurosci"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"1308972","DOI":"10.3389\/fncel.2023.1308972","volume":"17","author":"Y Morisaki","year":"2023","unstructured":"Morisaki Y, et al. LAG-3 expression in microglia regulated by IFN-gamma\/STAT1 pathway and metalloproteases. Front Cell Neurosci. 2023;17:1308972.","journal-title":"Front Cell Neurosci"},{"issue":"25","key":"797_CR13","doi-asserted-by":"publisher","first-page":"e2301903","DOI":"10.1002\/advs.202301903","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, et al. Cerebral microvascular Injury Induced by Lag3-Dependent alpha-synuclein Fibril Endocytosis exacerbates cognitive impairment in a mouse model of alpha-synucleinopathies. Adv Sci (Weinh). 2023;10(25):e2301903.","journal-title":"Adv Sci (Weinh)"},{"issue":"36","key":"797_CR14","doi-asserted-by":"publisher","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929\u201347.","journal-title":"J Neurosci"},{"issue":"9","key":"797_CR15","doi-asserted-by":"publisher","first-page":"e14745","DOI":"10.15252\/emmm.202114745","volume":"13","author":"M Emmenegger","year":"2021","unstructured":"Emmenegger M, et al. LAG3 is not expressed in human and murine neurons and does not modulate alpha-synucleinopathies. EMBO Mol Med. 2021;13(9):e14745.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"797_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/bio.2015.0032","volume":"13","author":"LJ Carithers","year":"2015","unstructured":"Carithers LJ, et al. A Novel Approach to High-Quality Postmortem tissue procurement: the GTEx Project. Biopreserv Biobank. 2015;13(5):311\u20139.","journal-title":"Biopreserv Biobank"},{"issue":"11","key":"797_CR17","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/gb-2009-10-11-r130","volume":"10","author":"C Wu","year":"2009","unstructured":"Wu C, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10(11):R130.","journal-title":"Genome Biol"},{"issue":"D1","key":"797_CR18","doi-asserted-by":"publisher","first-page":"D313","DOI":"10.1093\/nar\/gkv1104","volume":"44","author":"C Wu","year":"2016","unstructured":"Wu C, et al. BioGPS: building your own mash-up of gene annotations and expression profiles. Nucleic Acids Res. 2016;44(D1):D313\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"797_CR19","first-page":"D77","volume":"48","author":"I Papatheodorou","year":"2020","unstructured":"Papatheodorou I, et al. Expression Atlas update: from tissues to single cells. Nucleic Acids Res. 2020;48(D1):D77\u201383.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"797_CR20","doi-asserted-by":"publisher","first-page":"D129","DOI":"10.1093\/nar\/gkab1030","volume":"50","author":"P Moreno","year":"2022","unstructured":"Moreno P, et al. Expression Atlas update: gene and protein expression in multiple species. Nucleic Acids Res. 2022;50(D1):D129\u201340.","journal-title":"Nucleic Acids Res"},{"issue":"7124","key":"797_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature05453","volume":"445","author":"ES Lein","year":"2007","unstructured":"Lein ES, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445(7124):168\u201376.","journal-title":"Nature"},{"issue":"6","key":"797_CR22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GT Consortium","year":"2013","unstructured":"Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"797_CR23","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1038\/s41467-024-49016-3","volume":"15","author":"X Mao","year":"2024","unstructured":"Mao X, et al. Aplp1 interacts with Lag3 to facilitate transmission of pathologic alpha-synuclein. Nat Commun. 2024;15(1):4663.","journal-title":"Nat Commun"},{"key":"797_CR24","doi-asserted-by":"crossref","unstructured":"Chen C et al. Lymphocyte-activation gene 3 facilitates pathological tau neuron-to-Neuron transmission. Adv Sci (Weinh), 2024: p. e2303775.","DOI":"10.1002\/advs.202470092"},{"issue":"33","key":"797_CR25","doi-asserted-by":"publisher","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","volume":"110","author":"BB Holmes","year":"2013","unstructured":"Holmes BB, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110(33):E3138\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"797_CR26","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/brain\/awac171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan L, et al. Tau accelerates alpha-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain. 2022;145(10):3454\u201371.","journal-title":"Brain"},{"issue":"3","key":"797_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"L Fellner","year":"2013","unstructured":"Fellner L, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61(3):349\u201360.","journal-title":"Glia"},{"key":"797_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12868-015-0192-0","volume":"16","author":"EH Rannikko","year":"2015","unstructured":"Rannikko EH, Weber SS, Kahle PJ. Exogenous alpha-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci. 2015;16:57.","journal-title":"BMC Neurosci"},{"issue":"1","key":"797_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-018-1907-y","volume":"137","author":"CD Hughes","year":"2019","unstructured":"Hughes CD, et al. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson\u2019s disease pathogenesis. Acta Neuropathol. 2019;137(1):103\u201320.","journal-title":"Acta Neuropathol"},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbi.2018.12.003","volume":"76","author":"M Campolo","year":"2019","unstructured":"Campolo M, et al. TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson\u2019s diseases in vivo model. Brain Behav Immun. 2019;76:236\u201347.","journal-title":"Brain Behav Immun"},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.09.007","volume":"91","author":"S Venezia","year":"2021","unstructured":"Venezia S, et al. Toll-like receptor 4 deficiency facilitates alpha-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson\u2019s disease. Parkinsonism Relat Disord. 2021;91:59\u201365.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"797_CR32","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","volume":"11","author":"I Choi","year":"2020","unstructured":"Choi I, et al. Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration. Nat Commun. 2020;11(1):1386.","journal-title":"Nat Commun"},{"key":"797_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fphys.2017.00371","volume":"8","author":"MV Clausen","year":"2017","unstructured":"Clausen MV, Hilbers F, Poulsen H. The structure and function of the Na,K-ATPase isoforms in Health and Disease. Front Physiol. 2017;8:371.","journal-title":"Front Physiol"},{"issue":"19","key":"797_CR34","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.15252\/embj.201591397","volume":"34","author":"AN Shrivastava","year":"2015","unstructured":"Shrivastava AN, et al. Alpha-synuclein assemblies sequester neuronal alpha3-Na+\/K+-ATPase and impair na\u2009+\u2009gradient. EMBO J. 2015;34(19):2408\u201323.","journal-title":"EMBO J"},{"issue":"1","key":"797_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12974-020-01823-3","volume":"17","author":"L Hou","year":"2020","unstructured":"Hou L, et al. Integrin CD11b mediates locus coeruleus noradrenergic neurodegeneration in a mouse Parkinson\u2019s disease model. J Neuroinflammation. 2020;17(1):148.","journal-title":"J Neuroinflammation"},{"key":"797_CR36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.redox.2017.11.010","volume":"14","author":"L Hou","year":"2018","unstructured":"Hou L, et al. Integrin CD11b mediates alpha-synuclein-induced activation of NADPH oxidase through a rho-dependent pathway. Redox Biol. 2018;14:600\u20138.","journal-title":"Redox Biol"},{"key":"797_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fimmu.2019.00464","volume":"10","author":"JC Anania","year":"2019","unstructured":"Anania JC, et al. The human FcgammaRII (CD32) family of leukocyte FcR in Health and Disease. Front Immunol. 2019;10:464.","journal-title":"Front Immunol"},{"key":"797_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nbd.2015.08.025","volume":"83","author":"YR Choi","year":"2015","unstructured":"Choi YR, et al. FcgammaRIIB mediates the inhibitory effect of aggregated alpha-synuclein on microglial phagocytosis. Neurobiol Dis. 2015;83:90\u20139.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"797_CR39","doi-asserted-by":"publisher","first-page":"e48950","DOI":"10.15252\/embr.201948950","volume":"21","author":"YR Choi","year":"2020","unstructured":"Choi YR, et al. The dual role of c-src in cell-to-cell transmission of alpha-synuclein. EMBO Rep. 2020;21(7):e48950.","journal-title":"EMBO Rep"},{"issue":"4","key":"797_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s12031-021-01943-2","volume":"72","author":"L Song","year":"2022","unstructured":"Song L, et al. Heparan Sulfate proteoglycans (HSPGs) serve as the Mediator between Monomeric Tau and its subsequent intracellular ERK1\/2 pathway activation. J Mol Neurosci. 2022;72(4):772\u201391.","journal-title":"J Mol Neurosci"},{"key":"797_CR41","doi-asserted-by":"publisher","first-page":"671458","DOI":"10.3389\/fmolb.2021.671458","volume":"8","author":"D Mah","year":"2021","unstructured":"Mah D, et al. The Sulfation Code of tauopathies: Heparan Sulfate proteoglycans in the Prion like Spread of Tau Pathology. Front Mol Biosci. 2021;8:671458.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"797_CR42","doi-asserted-by":"publisher","first-page":"16543","DOI":"10.1038\/s41598-019-53038-z","volume":"9","author":"A Hudak","year":"2019","unstructured":"Hudak A, et al. Contribution of syndecans to cellular uptake and fibrillation of alpha-synuclein and tau. Sci Rep. 2019;9(1):16543.","journal-title":"Sci Rep"},{"issue":"7803","key":"797_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580(7803):381\u20135.","journal-title":"Nature"},{"key":"797_CR44","doi-asserted-by":"crossref","unstructured":"Chen M et al. Heparan sulfate proteoglycans mediate prion-like alpha-synuclein toxicity in Parkinson\u2019s in vivo models. Life Sci Alliance, 2022. 5(11).","DOI":"10.26508\/lsa.202201366"},{"issue":"4","key":"797_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/19336896.2017.1334748","volume":"11","author":"L Urrea","year":"2017","unstructured":"Urrea L, et al. The cellular prion protein (PrP(C)) as neuronal receptor for alpha-synuclein. Prion. 2017;11(4):226\u201333.","journal-title":"Prion"},{"issue":"3","key":"797_CR46","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s12035-017-0451-4","volume":"55","author":"L Urrea","year":"2018","unstructured":"Urrea L, et al. Involvement of Cellular prion protein in alpha-synuclein transport in neurons. Mol Neurobiol. 2018;55(3):1847\u201360.","journal-title":"Mol Neurobiol"},{"key":"797_CR47","doi-asserted-by":"crossref","unstructured":"Ferreira DG et al. alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci, 2017. 20(11): pp. 1569\u20131579.","DOI":"10.1038\/nn.4648"},{"key":"797_CR48","doi-asserted-by":"publisher","first-page":"674739","DOI":"10.3389\/fimmu.2021.674739","volume":"12","author":"M Saade","year":"2021","unstructured":"Saade M, et al. The role of GPNMB in inflammation. Front Immunol. 2021;12:674739.","journal-title":"Front Immunol"},{"issue":"2","key":"797_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5582\/irdr.2019.01049","volume":"8","author":"JI Satoh","year":"2019","unstructured":"Satoh JI, et al. Microglia express GPNMB in the brains of Alzheimer\u2019s disease and Nasu-Hakola disease. Intractable Rare Dis Res. 2019;8(2):120\u20138.","journal-title":"Intractable Rare Dis Res"},{"issue":"10","key":"797_CR50","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet. 2017;49(10):1511\u20136.","journal-title":"Nat Genet"},{"issue":"12","key":"797_CR51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091\u2013102.","journal-title":"Lancet Neurol"},{"issue":"6608","key":"797_CR52","doi-asserted-by":"publisher","first-page":"eabk0637","DOI":"10.1126\/science.abk0637","volume":"377","author":"ME Diaz-Ortiz","year":"2022","unstructured":"Diaz-Ortiz ME, et al. GPNMB confers risk for Parkinson\u2019s disease through interaction with alpha-synuclein. Science. 2022;377(6608):eabk0637.","journal-title":"Science"},{"key":"797_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.08.013","volume":"120","author":"EB Moloney","year":"2018","unstructured":"Moloney EB, et al. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson\u2019s disease patients and increases after lysosomal stress. Neurobiol Dis. 2018;120:1\u201311.","journal-title":"Neurobiol Dis"},{"key":"797_CR54","doi-asserted-by":"publisher","first-page":"105494","DOI":"10.1016\/j.nbd.2021.105494","volume":"159","author":"R Brendza","year":"2021","unstructured":"Brendza R, et al. Genetic ablation of Gpnmb does not alter synuclein-related pathology. Neurobiol Dis. 2021;159:105494.","journal-title":"Neurobiol Dis"},{"key":"797_CR55","doi-asserted-by":"publisher","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","volume":"13","author":"JL Huo","year":"2022","unstructured":"Huo JL, et al. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;13:956090.","journal-title":"Front Immunol"},{"key":"797_CR56","doi-asserted-by":"crossref","unstructured":"Karlsson M et al. A single-cell type transcriptomics map of human tissues. Sci Adv, 2021. 7(31).","DOI":"10.1126\/sciadv.abh2169"},{"issue":"2","key":"797_CR57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18(2):101\u201313.","journal-title":"Nat Rev Neurosci"},{"key":"797_CR58","doi-asserted-by":"crossref","unstructured":"Park H et al. Alpha-synuclein pathology as a target in neurodegenerative diseases. Nat Rev Neurol, 2024.","DOI":"10.1038\/s41582-024-01043-w"},{"key":"797_CR59","doi-asserted-by":"crossref","unstructured":"Deyell JS et al. The interplay between alpha-synuclein and Microglia in alpha-synucleinopathies. Int J Mol Sci, 2023. 24(3).","DOI":"10.3390\/ijms24032477"},{"issue":"7","key":"797_CR60","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1172\/JCI66827","volume":"123","author":"TI Kam","year":"2013","unstructured":"Kam TI, et al. FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer\u2019s disease. J Clin Invest. 2013;123(7):2791\u2013802.","journal-title":"J Clin Invest"},{"issue":"4","key":"797_CR61","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.celrep.2019.06.073","volume":"28","author":"S Canchi","year":"2019","unstructured":"Canchi S, et al. Integrating Gene and protein expression reveals perturbed functional networks in Alzheimer\u2019s Disease. Cell Rep. 2019;28(4):1103\u2013e11164.","journal-title":"Cell Rep"},{"issue":"2","key":"797_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"N Dzamko","year":"2017","unstructured":"Dzamko N, et al. Toll-like receptor 2 is increased in neurons in Parkinson\u2019s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 2017;133(2):303\u201319.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"797_CR63","doi-asserted-by":"publisher","first-page":"102260","DOI":"10.1016\/j.jbc.2022.102260","volume":"298","author":"J Chedid","year":"2022","unstructured":"Chedid J, et al. A small molecule toll-like receptor antagonist rescues alpha-synuclein fibril pathology. J Biol Chem. 2022;298(8):102260.","journal-title":"J Biol Chem"},{"key":"797_CR64","doi-asserted-by":"crossref","unstructured":"Cao L et al. Anti-na(+)\/K(+)-ATPase immunotherapy ameliorates alpha-synuclein pathology through activation of na(+)\/K(+)-ATPase alpha1-dependent autophagy. Sci Adv, 2021. 7(5).","DOI":"10.1126\/sciadv.abc5062"},{"key":"797_CR65","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","volume":"14","author":"L Chocarro","year":"2022","unstructured":"Chocarro L, et al. Clinical landscape of LAG-3-targeted therapy. Immunooncol Technol. 2022;14:100079.","journal-title":"Immunooncol Technol"},{"issue":"5","key":"797_CR66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/jnc.14713","volume":"150","author":"NN Vaikath","year":"2019","unstructured":"Vaikath NN, et al. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150(5):612\u201325.","journal-title":"J Neurochem"},{"issue":"2","key":"797_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"797_CR68","doi-asserted-by":"crossref","unstructured":"Hawkes CH, Del K, Tredici, Braak H. Parkinson\u2019s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33(6):599\u2013614.","DOI":"10.1111\/j.1365-2990.2007.00874.x"},{"issue":"5","key":"797_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501\u20133.","journal-title":"Nat Med"},{"issue":"5","key":"797_CR70","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14(5):504\u20136.","journal-title":"Nat Med"},{"issue":"23","key":"797_CR71","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1073\/pnas.1605245113","volume":"113","author":"W Li","year":"2016","unstructured":"Li W, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A. 2016;113(23):6544\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"797_CR72","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1212\/WNL.57.3.456","volume":"57","author":"RD Abbott","year":"2001","unstructured":"Abbott RD, et al. Frequency of bowel movements and the future risk of Parkinson\u2019s disease. Neurology. 2001;57(3):456\u201362.","journal-title":"Neurology"},{"issue":"21","key":"797_CR73","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e3181c34af5","volume":"73","author":"R Savica","year":"2009","unstructured":"Savica R, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 2009;73(21):1752\u20138.","journal-title":"Neurology"},{"issue":"5","key":"797_CR74","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s00415-012-6801-2","volume":"260","author":"MG Cersosimo","year":"2013","unstructured":"Cersosimo MG, et al. Gastrointestinal manifestations in Parkinson\u2019s disease: prevalence and occurrence before motor symptoms. J Neurol. 2013;260(5):1332\u20138.","journal-title":"J Neurol"},{"issue":"2","key":"797_CR75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/ana.20160","volume":"56","author":"MM Ponsen","year":"2004","unstructured":"Ponsen MM, et al. Idiopathic hyposmia as a preclinical sign of Parkinson\u2019s disease. Ann Neurol. 2004;56(2):173\u201381.","journal-title":"Ann Neurol"},{"issue":"11","key":"797_CR76","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24(11):1641\u20139.","journal-title":"Mov Disord"},{"issue":"4","key":"797_CR77","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, et al. Transneuronal Propagation of pathologic alpha-synuclein from the gut to the Brain models Parkinson\u2019s Disease. Neuron. 2019;103(4):627\u2013e6417.","journal-title":"Neuron"},{"issue":"4","key":"797_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5607\/en.2011.20.4.181","volume":"20","author":"HJ Lee","year":"2011","unstructured":"Lee HJ, et al. Transmission of synucleinopathies in the enteric nervous system of A53T alpha-synuclein transgenic mice. Exp Neurobiol. 2011;20(4):181\u20138.","journal-title":"Exp Neurobiol"},{"issue":"5","key":"797_CR79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209(5):975\u201386.","journal-title":"J Exp Med"},{"issue":"21","key":"797_CR80","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1016\/j.neuron.2024.10.015","volume":"112","author":"L Li","year":"2024","unstructured":"Li L, Dawson VL, Dawson TM. Gastrointestinal tract cleavage of alpha-synuclein by asparaginyl endopeptidase leads to Parkinson\u2019s disease. Neuron. 2024;112(21):3516\u20138.","journal-title":"Neuron"},{"issue":"21","key":"797_CR81","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.neuron.2024.08.003","volume":"112","author":"J Xiang","year":"2024","unstructured":"Xiang J, et al. Gut-induced alpha-synuclein and tau propagation initiate Parkinson\u2019s and Alzheimer\u2019s disease co-pathology and behavior impairments. Neuron. 2024;112(21):3585\u2013e36015.","journal-title":"Neuron"},{"issue":"6109","key":"797_CR82","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949\u201353.","journal-title":"Science"},{"key":"797_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-015-0254-7","volume":"3","author":"ME Bernis","year":"2015","unstructured":"Bernis ME, et al. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun. 2015;3:75.","journal-title":"Acta Neuropathol Commun"},{"issue":"13","key":"797_CR84","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1212\/01.wnl.0000306697.48738.b6","volume":"70","author":"J Zaccai","year":"2008","unstructured":"Zaccai J, et al. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology. 2008;70(13):1042\u20138.","journal-title":"Neurology"},{"issue":"3","key":"797_CR85","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2990.2007.00923.x","volume":"34","author":"ME Kalaitzakis","year":"2008","unstructured":"Kalaitzakis ME, et al. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson\u2019s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol. 2008;34(3):284\u201395.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"10","key":"797_CR86","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager J, et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020;143(10):3077\u201388.","journal-title":"Brain"},{"issue":"3","key":"797_CR87","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.nbd.2006.04.007","volume":"23","author":"M Maingay","year":"2006","unstructured":"Maingay M, et al. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol Dis. 2006;23(3):522\u201332.","journal-title":"Neurobiol Dis"},{"issue":"18","key":"797_CR88","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","volume":"25","author":"C Pacelli","year":"2015","unstructured":"Pacelli C, et al. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol. 2015;25(18):2349\u201360.","journal-title":"Curr Biol"},{"issue":"2","key":"797_CR89","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1523\/JNEUROSCI.4029-08.2009","volume":"29","author":"W Matsuda","year":"2009","unstructured":"Matsuda W, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci. 2009;29(2):444\u201353.","journal-title":"J Neurosci"},{"issue":"2","key":"797_CR90","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.mcn.2010.12.004","volume":"46","author":"S Nath","year":"2011","unstructured":"Nath S, et al. Raised calcium promotes alpha-synuclein aggregate formation. Mol Cell Neurosci. 2011;46(2):516\u201326.","journal-title":"Mol Cell Neurosci"},{"key":"797_CR91","doi-asserted-by":"crossref","unstructured":"Henrich MT et al. Determinants of seeding and spreading of alpha-synuclein pathology in the brain. Sci Adv, 2020. 6(46).","DOI":"10.1126\/sciadv.abc2487"},{"issue":"2","key":"797_CR92","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer B, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213(2):315\u201325.","journal-title":"Exp Neurol"},{"issue":"9","key":"797_CR93","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.biocel.2008.01.017","volume":"40","author":"HJ Lee","year":"2008","unstructured":"Lee HJ, et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008;40(9):1835\u201349.","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"797_CR94","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1073\/pnas.1013225108","volume":"108","author":"L Giehm","year":"2011","unstructured":"Giehm L, et al. Low-resolution structure of a vesicle disrupting \u03b1-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci U S A. 2011;108(8):3246\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"797_CR95","doi-asserted-by":"publisher","first-page":"19366","DOI":"10.1021\/ja2029848","volume":"133","author":"NP Reynolds","year":"2011","unstructured":"Reynolds NP, et al. Mechanism of membrane interaction and disruption by alpha-synuclein. J Am Chem Soc. 2011;133(48):19366\u201375.","journal-title":"J Am Chem Soc"},{"issue":"11","key":"797_CR96","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1016\/j.bbamem.2012.07.007","volume":"1818","author":"L Tosatto","year":"2012","unstructured":"Tosatto L, et al. Alpha-synuclein pore forming activity upon membrane association. Biochim Biophys Acta. 2012;1818(11):2876\u201383.","journal-title":"Biochim Biophys Acta"},{"key":"797_CR97","doi-asserted-by":"publisher","first-page":"114059","DOI":"10.1016\/j.bbr.2022.114059","volume":"436","author":"WP Ruf","year":"2023","unstructured":"Ruf WP, Meirelles JL, Danzer KM. Spreading of alpha-synuclein between different cell types. Behav Brain Res. 2023;436:114059.","journal-title":"Behav Brain Res"},{"issue":"25","key":"797_CR98","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","volume":"25","author":"HJ Lee","year":"2005","unstructured":"Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25(25):6016\u201324.","journal-title":"J Neurosci"},{"issue":"3","key":"797_CR99","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","volume":"42","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42(3):360\u20137.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"797_CR100","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1471-4159.2010.06695.x","volume":"113","author":"A Jang","year":"2010","unstructured":"Jang A, et al. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem. 2010;113(5):1263\u201374.","journal-title":"J Neurochem"},{"issue":"20","key":"797_CR101","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1523\/JNEUROSCI.5699-09.2010","volume":"30","author":"E Emmanouilidou","year":"2010","unstructured":"Emmanouilidou E, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30(20):6838\u201351.","journal-title":"J Neurosci"},{"key":"797_CR102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41421-018-0012-7","volume":"4","author":"Y Xu","year":"2018","unstructured":"Xu Y, et al. DNAJC5 facilitates USP19-dependent unconventional secretion of misfolded cytosolic proteins. Cell Discov. 2018;4:11.","journal-title":"Cell Discov"},{"issue":"7","key":"797_CR103","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ncb3372","volume":"18","author":"JG Lee","year":"2016","unstructured":"Lee JG, et al. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nat Cell Biol. 2016;18(7):765\u201376.","journal-title":"Nat Cell Biol"},{"key":"797_CR104","doi-asserted-by":"publisher","first-page":"957067","DOI":"10.3389\/fnmol.2022.957067","volume":"15","author":"S Lagalwar","year":"2022","unstructured":"Lagalwar S. Mechanisms of tunneling nanotube-based propagation of neurodegenerative disease proteins. Front Mol Neurosci. 2022;15:957067.","journal-title":"Front Mol Neurosci"},{"issue":"19","key":"797_CR105","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.15252\/embj.201593411","volume":"35","author":"S Abounit","year":"2016","unstructured":"Abounit S, et al. Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016;35(19):2120\u201338.","journal-title":"EMBO J"},{"key":"797_CR106","doi-asserted-by":"publisher","first-page":"p42984","DOI":"10.1038\/srep42984","volume":"7","author":"BV Dieriks","year":"2017","unstructured":"Dieriks BV, et al. Alpha-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson\u2019s disease patients. Sci Rep. 2017;7:p42984.","journal-title":"Sci Rep"},{"key":"797_CR107","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.nbd.2019.104609","volume":"132","author":"C Grudina","year":"2019","unstructured":"Grudina C, et al. Human NPCs can degrade alpha-syn fibrils and transfer them preferentially in a cell contact-dependent manner possibly through TNT-like structures. Neurobiol Dis. 2019;132:104609.","journal-title":"Neurobiol Dis"},{"issue":"23","key":"797_CR108","doi-asserted-by":"publisher","first-page":"e101230","DOI":"10.15252\/embj.2018101230","volume":"38","author":"JY Vargas","year":"2019","unstructured":"Vargas JY, et al. The Wnt\/Ca(2+) pathway is involved in interneuronal communication mediated by tunneling nanotubes. EMBO J. 2019;38(23):e101230.","journal-title":"EMBO J"},{"issue":"Suppl 1","key":"797_CR109","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/jnc.13449","volume":"139","author":"T Tyson","year":"2016","unstructured":"Tyson T, Steiner JA, Brundin P. Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem. 2016;139(Suppl 1):275\u201389.","journal-title":"J Neurochem"},{"issue":"1","key":"797_CR110","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1471-4159.2006.03731.x","volume":"97","author":"KJ Ahn","year":"2006","unstructured":"Ahn KJ, et al. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J Neurochem. 2006;97(1):265\u201379.","journal-title":"J Neurochem"},{"issue":"6369","key":"797_CR111","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco G, et al. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. Science. 2017;358(6369):1440\u20133.","journal-title":"Science"},{"issue":"2","key":"797_CR112","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41583-020-00416-6","volume":"22","author":"MB Fares","year":"2021","unstructured":"Fares MB, Jagannath S, Lashuel HA. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat Rev Neurosci. 2021;22(2):111\u201331.","journal-title":"Nat Rev Neurosci"},{"issue":"17","key":"797_CR113","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1021\/acschemneuro.0c00309","volume":"11","author":"J Parres-Gold","year":"2020","unstructured":"Parres-Gold J, et al. Real-time characterization of cell membrane disruption by alpha-synuclein oligomers in Live SH-SY5Y Neuroblastoma cells. ACS Chem Neurosci. 2020;11(17):2528\u201334.","journal-title":"ACS Chem Neurosci"},{"issue":"12","key":"797_CR114","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/cdd.2015.79","volume":"22","author":"AL Mahul-Mellier","year":"2015","unstructured":"Mahul-Mellier AL, et al. Fibril growth and seeding capacity play key roles in alpha-synuclein-mediated apoptotic cell death. Cell Death Differ. 2015;22(12):2107\u201322.","journal-title":"Cell Death Differ"},{"issue":"12","key":"797_CR115","doi-asserted-by":"publisher","first-page":"167930","DOI":"10.1016\/j.jmb.2022.167930","volume":"435","author":"S Neupane","year":"2023","unstructured":"Neupane S, De Cecco E, Aguzzi A. The hidden cell-to-cell trail of alpha-synuclein aggregates. J Mol Biol. 2023;435(12):167930.","journal-title":"J Mol Biol"},{"key":"797_CR116","doi-asserted-by":"publisher","first-page":"1081426","DOI":"10.3389\/fncel.2022.1081426","volume":"16","author":"JK Smith","year":"2022","unstructured":"Smith JK, Mellick GD, Sykes AM. The role of the endolysosomal pathway in alpha-synuclein pathogenesis in Parkinson\u2019s disease. Front Cell Neurosci. 2022;16:1081426.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"797_CR117","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI43366","volume":"121","author":"C Hansen","year":"2011","unstructured":"Hansen C, et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011;121(2):715\u201325.","journal-title":"J Clin Invest"},{"issue":"1","key":"797_CR118","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1038\/s41598-019-42161-6","volume":"9","author":"A Dilsizoglu Senol","year":"2019","unstructured":"Dilsizoglu Senol A, et al. Effect of tolytoxin on tunneling nanotube formation and function. Sci Rep. 2019;9(1):5741.","journal-title":"Sci Rep"},{"key":"797_CR119","doi-asserted-by":"crossref","unstructured":"Wong YC, Krainc D. alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med, 2017. 23(2): pp. 1\u201313.","DOI":"10.1038\/nm.4269"},{"issue":"1","key":"797_CR120","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41598-018-35811-8","volume":"9","author":"AC Hoffmann","year":"2019","unstructured":"Hoffmann AC, et al. Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. Sci Rep. 2019;9(1):544.","journal-title":"Sci Rep"},{"key":"797_CR121","doi-asserted-by":"crossref","unstructured":"Risiglione P et al. Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson\u2019s Disease: The Emerging Role of VDAC. Biomolecules, 2021. 11(5).","DOI":"10.3390\/biom11050718"},{"issue":"9","key":"797_CR122","doi-asserted-by":"publisher","first-page":"e0184040","DOI":"10.1371\/journal.pone.0184040","volume":"12","author":"L Zondler","year":"2017","unstructured":"Zondler L, et al. Proteasome impairment by alpha-synuclein. PLoS ONE. 2017;12(9):e0184040.","journal-title":"PLoS ONE"},{"key":"797_CR123","doi-asserted-by":"crossref","unstructured":"Bras IC, Outeiro TF. Alpha-Synuclein: mechanisms of Release and Pathology Progression in Synucleinopathies. Cells, 2021. 10(2).","DOI":"10.3390\/cells10020375"},{"issue":"6","key":"797_CR124","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00401-020-02227-6","volume":"140","author":"Q Wu","year":"2020","unstructured":"Wu Q, et al. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathol. 2020;140(6):831\u201349.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"797_CR125","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/brain\/awad150","volume":"146","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, et al. Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease. Brain. 2023;146(9):3587\u201397.","journal-title":"Brain"},{"issue":"17","key":"797_CR126","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1093\/hmg\/ddp265","volume":"18","author":"KD Cronin","year":"2009","unstructured":"Cronin KD, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet. 2009;18(17):3274\u201385.","journal-title":"Hum Mol Genet"},{"issue":"45","key":"797_CR127","doi-asserted-by":"publisher","first-page":"31190","DOI":"10.1074\/jbc.M109.057240","volume":"284","author":"SF Falsone","year":"2009","unstructured":"Falsone SF, et al. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem. 2009;284(45):31190\u20139.","journal-title":"J Biol Chem"},{"issue":"27","key":"797_CR128","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb JL, et al. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009\u201313.","journal-title":"J Biol Chem"},{"key":"797_CR129","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"CR Fields","year":"2019","unstructured":"Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a therapy for Parkinson\u2019s Disease. Front Mol Neurosci. 2019;12:299.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"797_CR130","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam P, et al. Alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem. 2019;150(5):522\u201334.","journal-title":"J Neurochem"},{"issue":"1","key":"797_CR131","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13024-018-0241-0","volume":"13","author":"K Yamada","year":"2018","unstructured":"Yamada K, Iwatsubo T. Extracellular alpha-synuclein levels are regulated by neuronal activity. Mol Neurodegener. 2018;13(1):9.","journal-title":"Mol Neurodegener"},{"key":"797_CR132","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.brainres.2011.02.041","volume":"1386","author":"Y Han","year":"2011","unstructured":"Han Y, et al. A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res. 2011;1386:15\u201324.","journal-title":"Brain Res"},{"issue":"2","key":"797_CR133","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","volume":"198","author":"MK Sapru","year":"2006","unstructured":"Sapru MK, et al. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol. 2006;198(2):382\u201390.","journal-title":"Exp Neurol"},{"key":"797_CR134","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fneur.2017.00013","volume":"8","author":"YC Kim","year":"2017","unstructured":"Kim YC, et al. RNA interference of human alpha-synuclein in mouse. Front Neurol. 2017;8:13.","journal-title":"Front Neurol"},{"key":"797_CR135","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.nbd.2019.01.004","volume":"125","author":"A Zharikov","year":"2019","unstructured":"Zharikov A, et al. Long-term RNAi knockdown of alpha-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiol Dis. 2019;125:146\u201353.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"797_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.11001","volume":"4","author":"DM Maraganore","year":"2011","unstructured":"Maraganore DM. Rationale for therapeutic silencing of alpha-synuclein in Parkinson\u2019s disease. J Mov Disord. 2011;4(1):1\u20137.","journal-title":"J Mov Disord"},{"key":"797_CR137","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","volume":"9","author":"C Helmschrodt","year":"2017","unstructured":"Helmschrodt C, et al. Polyethylenimine nanoparticle-mediated siRNA delivery to reduce alpha-synuclein expression in a model of Parkinson\u2019s Disease. Mol Ther Nucleic Acids. 2017;9:57\u201368.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"797_CR138","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/mds.101","volume":"33","author":"K Xhima","year":"2018","unstructured":"Xhima K, et al. Noninvasive delivery of an alpha-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound. Mov Disord. 2018;33(10):1567\u201379.","journal-title":"Mov Disord"},{"issue":"2","key":"797_CR139","doi-asserted-by":"publisher","first-page":"e2306682120","DOI":"10.1073\/pnas.2306682120","volume":"121","author":"Y Tong","year":"2024","unstructured":"Tong Y, et al. Decreasing the intrinsically disordered protein alpha-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera. Proc Natl Acad Sci U S A. 2024;121(2):e2306682120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"797_CR140","doi-asserted-by":"publisher","first-page":"1034072","DOI":"10.3389\/fphar.2022.1034072","volume":"13","author":"V Suvarna","year":"2022","unstructured":"Suvarna V, Deshmukh K, Murahari M. miRNA and antisense oligonucleotide-based alpha-synuclein targeting as disease-modifying therapeutics in Parkinson\u2019s disease. Front Pharmacol. 2022;13:1034072.","journal-title":"Front Pharmacol"},{"key":"797_CR141","doi-asserted-by":"crossref","unstructured":"Cole TA et al. alpha-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease. JCI Insight, 2021. 6(5).","DOI":"10.1172\/jci.insight.135633"},{"key":"797_CR142","doi-asserted-by":"publisher","first-page":"102944","DOI":"10.1016\/j.ebiom.2020.102944","volume":"59","author":"D Alarcon-Aris","year":"2020","unstructured":"Alarcon-Aris D, et al. Anti-alpha-synuclein ASO delivered to monoamine neurons prevents alpha-synuclein accumulation in a Parkinson\u2019s disease-like mouse model and in monkeys. EBioMedicine. 2020;59:102944.","journal-title":"EBioMedicine"},{"key":"797_CR143","doi-asserted-by":"publisher","first-page":"105218","DOI":"10.1016\/j.nbd.2020.105218","volume":"148","author":"J Yang","year":"2021","unstructured":"Yang J, et al. Exosome-mediated delivery of antisense oligonucleotides targeting alpha-synuclein ameliorates the pathology in a mouse model of Parkinson\u2019s disease. Neurobiol Dis. 2021;148:105218.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"797_CR144","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1038\/s41598-019-43772-9","volume":"9","author":"T Uehara","year":"2019","unstructured":"Uehara T, et al. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting alpha-synuclein as a novel therapy for Parkinson\u2019s disease. Sci Rep. 2019;9(1):7567.","journal-title":"Sci Rep"},{"issue":"1","key":"797_CR145","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-024-01766-3","volume":"12","author":"T Sano","year":"2024","unstructured":"Sano T, et al. Effects of local reduction of endogenous alpha-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice. Acta Neuropathol Commun. 2024;12(1):75.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"797_CR146","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-021-00497-6","volume":"16","author":"KS Chen","year":"2021","unstructured":"Chen KS, et al. Small molecule inhibitors of alpha-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. Elegans. Mol Neurodegener. 2021;16(1):77.","journal-title":"Mol Neurodegener"},{"issue":"41","key":"797_CR147","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"J Pujols","year":"2018","unstructured":"Pujols J, et al. Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci U S A. 2018;115(41):10481\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"797_CR148","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2019","unstructured":"Heras-Garvin A, et al. Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019;34(2):255\u201363.","journal-title":"Mov Disord"},{"issue":"6","key":"797_CR149","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41401-022-01039-6","volume":"44","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. Pharmacological characterization of the small molecule 03A10 as an inhibitor of alpha-synuclein aggregation for Parkinson\u2019s disease treatment. Acta Pharmacol Sin. 2023;44(6):1122\u201334.","journal-title":"Acta Pharmacol Sin"},{"key":"797_CR150","doi-asserted-by":"crossref","unstructured":"Rosado-Ramos R et al. Genipin prevents alpha-synuclein aggregation and toxicity by affecting endocytosis, metabolism and lipid storage. Nat Commun, 2023. 14(1): p. 1918.","DOI":"10.1038\/s41467-023-37561-2"},{"key":"797_CR151","doi-asserted-by":"publisher","first-page":"104021","DOI":"10.1016\/j.ebiom.2022.104021","volume":"80","author":"J Levin","year":"2022","unstructured":"Levin J, et al. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine. 2022;80:104021.","journal-title":"EBioMedicine"},{"issue":"10","key":"797_CR152","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit JW, et al. Phase 1\/1b studies of UCB0599, an oral inhibitor of alpha-synuclein misfolding, including a Randomized Study in Parkinson\u2019s Disease. Mov Disord. 2022;37(10):2045\u201356.","journal-title":"Mov Disord"},{"issue":"1","key":"797_CR153","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","volume":"74","author":"H Grosso Jasutkar","year":"2022","unstructured":"Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting alpha-synuclein for Parkinson\u2019s Disease. Pharmacol Rev. 2022;74(1):207\u201337.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"797_CR154","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mds.26481","volume":"31","author":"AL Bergstrom","year":"2016","unstructured":"Bergstrom AL, Kallunki P, Fog K. Development of Passive immunotherapies for synucleinopathies. Mov Disord. 2016;31(2):203\u201313.","journal-title":"Mov Disord"},{"issue":"5","key":"797_CR155","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","volume":"19","author":"L Knecht","year":"2022","unstructured":"Knecht L, et al. Alpha-synuclein immunization strategies for synucleinopathies in Clinical studies: a Biological Perspective. Neurotherapeutics. 2022;19(5):1489\u2013502.","journal-title":"Neurotherapeutics"},{"key":"797_CR156","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.nbd.2021.105543","volume":"161","author":"E Nordstrom","year":"2021","unstructured":"Nordstrom E, et al. ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson\u2019s disease. Neurobiol Dis. 2021;161:105543.","journal-title":"Neurobiol Dis"},{"key":"797_CR157","unstructured":"Kalluri H et al. Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects, in MDS Virtual Congress 2021. 2021."},{"key":"797_CR158","unstructured":"Taylor NP. AbbVie shreds alpha-synuclein Parkinson\u2019s pact on cusp of phase 2, thinning field led by Roche. Fierce Biotech; 2022."},{"issue":"6","key":"797_CR159","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/mds.29784","volume":"39","author":"L Buur","year":"2024","unstructured":"Buur L, et al. Randomized Phase I trial of the alpha-synuclein antibody Lu AF82422. Mov Disord. 2024;39(6):936\u201344.","journal-title":"Mov Disord"},{"key":"797_CR160","unstructured":"Lundbeck H. Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD\/PD 2024 conference on neurodegenerative disorders. 2024."},{"key":"797_CR161","unstructured":"Likelihood of Approval and Phase Transition Success Rate Model \u2013 UCB-7853 in Parkinson\u2019s Disease. 2024."},{"issue":"8","key":"797_CR162","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.27738","volume":"34","author":"M Brys","year":"2019","unstructured":"Brys M, et al. Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054. Mov Disord. 2019;34(8):1154\u201363.","journal-title":"Mov Disord"},{"issue":"5","key":"797_CR163","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, et al. Trial of Cinpanemab in Early Parkinson\u2019s Disease. N Engl J Med. 2022;387(5):408\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"797_CR164","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson Disease: a Randomized Clinical Trial. JAMA Neurol. 2018;75(10):1206\u201314.","journal-title":"JAMA Neurol"},{"issue":"5","key":"797_CR165","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. 2022;387(5):421\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"797_CR166","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med. 2024;30(4):1096\u2013103.","journal-title":"Nat Med"},{"issue":"7","key":"797_CR167","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"D Volc","year":"2020","unstructured":"Volc D, et al. Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19(7):591\u2013600.","journal-title":"Lancet Neurol"},{"issue":"3","key":"797_CR168","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JPD-212594","volume":"11","author":"W Poewe","year":"2021","unstructured":"Poewe W, et al. Safety and tolerability of active immunotherapy targeting alpha-synuclein with PD03A in patients with early Parkinson\u2019s Disease: a randomized, Placebo-Controlled, phase 1 study. J Parkinsons Dis. 2021;11(3):1079\u201389.","journal-title":"J Parkinsons Dis"},{"issue":"11","key":"797_CR169","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/mds.28218","volume":"35","author":"WG Meissner","year":"2020","unstructured":"Meissner WG, et al. A phase 1 Randomized Trial of specific active alpha-synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord. 2020;35(11):1957\u201365.","journal-title":"Mov Disord"},{"issue":"7","key":"797_CR170","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/mds.29016","volume":"37","author":"HJ Yu","year":"2022","unstructured":"Yu HJ, et al. A Randomized First-in-human study with UB-312, a UBITh(R) alpha-synuclein peptide vaccine. Mov Disord. 2022;37(7):1416\u201324.","journal-title":"Mov Disord"},{"issue":"15","key":"797_CR171","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1111\/febs.16376","volume":"289","author":"I Hmila","year":"2022","unstructured":"Hmila I, et al. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity. FEBS J. 2022;289(15):4657\u201373.","journal-title":"FEBS J"},{"key":"797_CR172","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","volume":"4","author":"D Chatterjee","year":"2018","unstructured":"Chatterjee D, et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson\u2019s disease model. NPJ Parkinsons Dis. 2018;4:25.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"797_CR173","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12915-017-0390-6","volume":"15","author":"M Iljina","year":"2017","unstructured":"Iljina M, et al. Nanobodies raised against monomeric a-synuclein inhibit fibril formation and destabilize toxic oligomeric species. BMC Biol. 2017;15(1):57.","journal-title":"BMC Biol"},{"issue":"1","key":"797_CR174","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1038\/s41467-022-31787-2","volume":"13","author":"YR Butler","year":"2022","unstructured":"Butler YR, et al. Alpha-synuclein fibril-specific nanobody reduces prion-like alpha-synuclein spreading in mice. Nat Commun. 2022;13(1):4060.","journal-title":"Nat Commun"},{"issue":"1","key":"797_CR175","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-024-00407-y","volume":"13","author":"W Li","year":"2024","unstructured":"Li W, Li JY. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration. Transl Neurodegener. 2024;13(1):16.","journal-title":"Transl Neurodegener"},{"key":"797_CR176","doi-asserted-by":"crossref","unstructured":"Ayers JI et al. Different alpha-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Natl Acad Sci U S A, 2022. 119(6).","DOI":"10.1073\/pnas.2113489119"},{"key":"797_CR177","doi-asserted-by":"crossref","unstructured":"Konickova D et al. Biomarkers of neurodegenerative diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status. Biomedicines, 2022. 10(7).","DOI":"10.3390\/biomedicines10071760"},{"issue":"1","key":"797_CR178","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","volume":"154","author":"JL Guo","year":"2013","unstructured":"Guo JL, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154(1):103\u201317.","journal-title":"Cell"},{"issue":"42","key":"797_CR179","doi-asserted-by":"publisher","first-page":"E6506","DOI":"10.1073\/pnas.1606791113","volume":"113","author":"A Villar-Pique","year":"2016","unstructured":"Villar-Pique A, et al. Environmental and genetic factors support the dissociation between alpha-synuclein aggregation and toxicity. Proc Natl Acad Sci U S A. 2016;113(42):E6506\u201315.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2\u20133","key":"797_CR180","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000511083","volume":"20","author":"S He","year":"2020","unstructured":"He S, et al. Alpha-Synuclein: the interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson\u2019s Disease. Neurodegener Dis. 2020;20(2\u20133):55\u201364.","journal-title":"Neurodegener Dis"},{"issue":"6645","key":"797_CR181","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"1","key":"797_CR182","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-022-00579-z","volume":"17","author":"K Reddy","year":"2022","unstructured":"Reddy K, Dieriks BV. Multiple system atrophy: alpha-synuclein strains at the neuron-oligodendrocyte crossroad. Mol Neurodegener. 2022;17(1):77.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"797_CR183","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1038\/s41467-022-32625-1","volume":"13","author":"YX Xie","year":"2022","unstructured":"Xie YX, et al. Lysosomal exocytosis releases pathogenic alpha-synuclein species from neurons in synucleinopathy models. Nat Commun. 2022;13(1):4918.","journal-title":"Nat Commun"},{"issue":"11","key":"797_CR184","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s11064-020-03126-8","volume":"45","author":"AC Nascimento","year":"2020","unstructured":"Nascimento AC, et al. Alpha-synuclein overexpression induces lysosomal dysfunction and autophagy impairment in Human Neuroblastoma SH-SY5Y. Neurochem Res. 2020;45(11):2749\u201361.","journal-title":"Neurochem Res"},{"issue":"1","key":"797_CR185","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13024-023-00675-8","volume":"18","author":"SG Allen","year":"2023","unstructured":"Allen SG, et al. Peptide-based approaches to directly target alpha-synuclein in Parkinson\u2019s disease. Mol Neurodegener. 2023;18(1):80.","journal-title":"Mol Neurodegener"},{"key":"797_CR186","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","volume":"9","author":"K Naran","year":"2018","unstructured":"Naran K, et al. Principles of Immunotherapy: implications for treatment strategies in Cancer and Infectious diseases. Front Microbiol. 2018;9:3158.","journal-title":"Front Microbiol"},{"issue":"1","key":"797_CR187","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","volume":"109","author":"DR Goulet","year":"2020","unstructured":"Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109(1):74\u2013103.","journal-title":"J Pharm Sci"},{"issue":"8","key":"797_CR188","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/brain\/awz172","volume":"142","author":"S Brahmachari","year":"2019","unstructured":"Brahmachari S, et al. Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson\u2019s disease. Brain. 2019;142(8):2380\u2013401.","journal-title":"Brain"},{"key":"797_CR189","doi-asserted-by":"crossref","unstructured":"Jo A et al. PARIS farnesylation prevents neurodegeneration in models of Parkinson\u2019s disease. Sci Transl Med, 2021. 13(604).","DOI":"10.1126\/scitranslmed.aax8891"},{"key":"797_CR190","doi-asserted-by":"crossref","unstructured":"Kam TI et al. Poly(ADP-ribose) drives pathologic alpha-synuclein neurodegeneration in Parkinson\u2019s disease. Science, 2018. 362(6414).","DOI":"10.1126\/science.aat8407"},{"issue":"23","key":"797_CR191","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1016\/j.neuron.2021.09.031","volume":"109","author":"BA Seo","year":"2021","unstructured":"Seo BA, et al. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson\u2019s disease. Neuron. 2021;109(23):3758\u2013e377411.","journal-title":"Neuron"},{"issue":"5","key":"797_CR192","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s12264-023-01023-y","volume":"39","author":"QQ Han","year":"2023","unstructured":"Han QQ, Le W. NLRP3 inflammasome-mediated neuroinflammation and related mitochondrial impairment in Parkinson\u2019s Disease. Neurosci Bull. 2023;39(5):832\u201344.","journal-title":"Neurosci Bull"},{"key":"797_CR193","doi-asserted-by":"crossref","unstructured":"Liu YQ et al. Nanozyme scavenging ROS for prevention of pathologic \u03b1-synuclein transmission in Parkinson\u2019s disease. Nano Today, 2021. 36.","DOI":"10.1016\/j.nantod.2020.101027"},{"key":"797_CR194","doi-asserted-by":"crossref","unstructured":"Li Q et al. Metal-Organic Framework Based Nanozyme System for NLRP3 Inflammasome-Mediated Neuroinflammatory Regulation in Parkinson\u2019s Disease. Adv Healthc Mater, 2023: p. e2303454.","DOI":"10.1002\/adhm.202303454"},{"issue":"1","key":"797_CR195","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stemcr.2023.11.009","volume":"19","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Interspecies chimerism with human embryonic stem cells generates functional human dopamine neurons at low efficiency. Stem Cell Rep. 2024;19(1):54\u201367.","journal-title":"Stem Cell Rep"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00797-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:17:33Z","timestamp":1737613053000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00797-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":195,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00797-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.M.D., V.L.D. and X.B.M. has filed a patent for therapeutic uses of Lag3 (application No: PCT\/US2017\/047878). X.B.M. and R.K. has a patent filed for use of nanobody PFF-NB2 to treat \u03b1-synucleinopathies (application no: PCT\/US2022\/037038). XBM has a patent filed for use of nanozymes for treating neurodegenerative diseases (application no: PCT\/US2023\/078741, PCT\/US2021\/059530). All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}